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Background: The clinical features, physiology, and pathology of severe asthma are poorly
understood. Recently, the forced vital capacity (FVC) has been shown to be reduced in severe
asthma compared to mild asthma, possibly due to air trapping. However, the natural history
and risk factors of obstructive change for such asthmatic patients have not been fully eluci-
dated.
Methods: We examined the data of a retrospective analysis of lung function changes over a 10-
year period in 54 severe asthma patients.
Results: The faster obstructive changes detected by FEV1 (forced expiratory volume in one
second) were accompanied by excessive loss of FVC (r Z 0.85, p < 0.0001) and the reduction
in FVC was 1.2 times larger than the FEV1 change. Age, baseline FVC, exacerbation rate and
oral corticosteroids use showed significantly negative correlations with the rate of annual
change in FVC.
Conclusions: These data indicate that the decline in FVC is more evident than FEV1 in severe
asthma, suggesting that small airway susceptibility may be the cause of rapid disease progres-
sion. Aging, exacerbations of asthma, and use of systemic corticosteroids are related to excess
FVC decline, particularly if FVC is still normal.
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356 K. Matsunaga et al.Introduction Study subjectsAirflow limitation in asthma is due mainly to airway smooth
muscle contraction, but airway mucosal edema, vascular
congestion, and luminal occlusion by exudate may also
contribute. In a subset of patients with asthma, early
closure of the small airway results in air trapping and
increased residual volume (RV).1 Worsening of forced
expiratory volume in one second (FEV1)/forced vital
capacity (FVC) indicates increasing airway narrowing,
whereas decreasing FVC suggests worsening air trapping.2
A force that opposes airway narrowing/closure is the
circumferential traction on the airways by the tethering
effect of lung elastic recoil.3,4 Therefore, a reduction of
lung elasticity could contribute to air trapping in asthma.
Importantly, air trapping has been reported to be associ-
ated with poorly controlled asthma and with asthma
exacerbations.5,6
Asthma is a highly reversible disease and the majority of
cases can be controlled by usual therapy such as inhaled
corticosteroids (ICS). However, less than 5% of total asthma
is severe/refractory asthma, and its clinical features,
physiology, and pathology are poorly understood.7 In
a longitudinal study, substantially greater declines in FEV1
have been reported in adult asthma.8 Rapid loss of FEV1
seems mainly due to airway narrowing and, partially, to the
loss of lung elasticity, and these factors are the possible
causes of severe/refractory asthma.7,9 Recently, the FVC
has been reported to be reduced in severe asthma
compared to mild asthma, possibly due to air trapping.2,9
However, the natural history and risk factors for such
asthmatic patients have not been fully elucidated.
In this study, we examined the data of a retrospective
analysis of airway obstructive changes over time obtained
from outpatients of a clinic located in an urban area of
Japan. A total of 54 severe asthmatic patients in whom
lung function tests were performed for more than 10
years, was included in this analysis. It is well known that
an excess decline in lung function does not occur in all
asthmatic patients.8,10,11 The risk factors that might
contribute to the progression of obstructive changes were
also investigated.
Methods
Study design
This was a retrospective observational study to assess the
natural history and risk factors of airway obstructive
changes in patients with severe asthma. All subjects
attended the clinic on a regular basis and were closely
followed with spirometry at every visit. The pre-
bronchodilator FVC and FEV1 were measured according to
the standard procedure.12 Medical records including age,
body mass index, smoking history, medication use, and
exacerbations of asthma were obtained. Complete blood
cell count, total serum immunoglobulin E (IgE), and specific
IgE for inhaled allergens (housedust, mite, cedar, cypress,
and ragweed) were also evaluated. Positive specific IgE to
at least one common allergen was assumed to confirm the
presence of atopy.All subjects were followed from October 1991 to February
2007 at Miyatake Asthma Clinic located in an urban area of
Japan (Osaka). Subjects over 25 years old were eligible if
they satisfied the standard criteria for asthma.12 Asthma
was diagnosed on the basis of the presence of significant
airway reversibility and/or airway hyperresponsiveness
during the study period.12 The criterion for refractory
asthma from the American Thoracic Society (ATS) was used
to determine the severity classifications at baseline.7 The
definition of severe asthma requires a combination of 1 of 2
major and 2 of 7 minor criteria and identifies subjects with
poor asthma control despite treatment with high-daily-dose
ICS (>equivalent dose of 1260 mg beclomethasone dipropi-
onate/day).7 In total, 54 severe asthmatic patients in whom
lung function tests were performed for more than 10 years
were included in this analysis. Subjects with poor adher-
ence to the treatment or with other pulmonary and/or
cardiac diseases were excluded. All smokers and patients
with chronic rhinosinusitis had chest computed tomography
to exclude clinically occult pulmonary emphysema or
bronchiectasis. Specific IgE for fungus and anti-neutrophil
cytoplasmic antibody was examined to exclude allergic
bronchopulmonary aspergillosis or allergic granulomatous
angitis at the discretion of the physician. Asthma treatment
was standardized and directed by the same clinician
throughout the study period and included ICS, inhaled long-
acting b2-agonist, leukotriene receptor antagonist,
theophylline, and intermittent courses of oral corticoste-
roid (OCS) and/or continuous low-dose OCS (<10 mg/day).
Mean daily doses of ICS were expressed as beclomethasone
dipropionate equivalent. Asthma exacerbations were
defined as events that required urgent action for worsening
asthma including unscheduled office visits, emergency
department visits, or hospitalization requiring systemic
steroids therapy.13 This study was approved by the local
ethics committee and informed written consent for using
the data was obtained from each subject.
Statistical analysis
All data were expressed as mean values  SD for continuous
variables. For categorical variables, the numbers of obser-
vations and percentages were given in each category.
Comparisons between different subgroups were performed
by Fisher’s exact test and KruskaleWallis test. Spearman’s
correlation analysis was performed to assess the correlation
between the annual rate of change in FVC and age, baseline
FVC, exacerbation rate, and frequency of OCS use. The
significance level was set at p <0.05.
Results
The baseline characteristics are listed in Table 1. The
subjects consisted of 28 males and 26 females with an
average age of 50.3 years. Despite treatment with high-
daily-dose ICS (mean equivalent dose of 1920 mg beclome-
thasone dipropionate/day at baseline), the subjects had an
average of 4e5 total minor criteria of ATS definition (Table
2).7 All subjects were using a second controller medication,
Table 1 Baseline characteristics of study subjects.
Number (female/male) 54 (26/28)
Age (years) 50.3  12.9
Body mass index (kg/mm2) 23.5  3.5
Smoking status (never/ex/current) 29/18/7
Smoking index (pack-years) 18.5  17.5
Atopy, n (%) 48 (88.9)
Blood eosinophil count (%) 13.8  6.9
Serum total immunoglobulin E (IU/mL) 1335  1879
FVC (L) 2.65  0.73
FVC % of predicted (%) 82.6  14.6
FEV1 (L) 1.81  0.59
FEV1/FVC ratio (%) 67.8  10.3
FEV1% of predicted (%) 55.9  12.7
Values are means  SD.
Table 3 Clinical course during follow-up period.
Duration of the follow-up (years) 12.7  1.1
Number of pulmonary function test (times) 112  40
Visit interval (weeks) 6.9  3.2
Use of inhaled corticosteroids, n (%) 54 (100.0)
Dose of inhaled corticosteroids (mg/day)a 1830  592
Use of inhaled long-acting b2-agonist, n (%) 38 (70.4)
Use of leukotriene receptor antagonist, n (%) 16 (29.6)
Use of theophylline, n (%) 39 (72.2)
Annual use of oral corticosteroids (days/year) 67.3  62.9
Number of exacerbation (times) 6.2  6.9
Annual exacerbation rate (events/year) 0.48  0.51
Annual rates of change in FVC (mL/year) 9.1  49.2
Annual rates of change in FEV1 (mL/year) 0.6  34.7
Values are means  SD.
a Inhaled corticosteroids, expressed as beclomethasone
dipropionate equivalent.
Changes in airway obstruction in severe asthma 357had asthma symptoms requiring short-acting b2-agonist use
on a near-daily basis, and had persistent airflow limitation,
and more than half were having frequent exacerbations
that required urgent care visits or treatment with OCS burst
during the past year.
Table 3 shows the clinical course during follow-up period
of 12.7 years average. The majority (87%) of the subjects
experienced at least one exacerbation with a mean rate of
0.48/year, and 53 subjects (98%) received at least one
intermittent and/or continuous courses of OCS. A total of
6047 lung function tests were analyzed. The mean annual
rate of change in FVC (DFVC) was 9.1 mL/year and the
mean annual rate of change in FEV1 (DFEV1) was þ0.6 mL/
year. The rate of change in both FVC and FEV1 was highly
variable, and approximately one in three subjects (31%) had
an estimated rate of FVC decline of more than 20 mL/year
(Fig. 1). The relationship between DFEV1 and DFVC over
time is shown in Fig. 2. The DFEV1 was significantly corre-
lated with the DFVC (rZ 0.85, p < 0.0001). In addition, the
DFVC was about 1.2 times larger than the DFEV1.Table 2 Frequency of ATS severe asthma criteria7 at
baseline.
Number (%)
Major criteria
Oral corticosteroids for 50% of year 8 (15)
High-dose inhaled corticosteroidsa 54 (100)
Minor criteria
Daily second controller medication 54 (100)
Near-daily basis short-acting b2-agonist useb 54 (100)
Persistent airflow limitationc 54 (100)
1 urgent care visit/year 28 (52)
3 oral corticosteroids burst/year 30 (56)
Deterioration with reduced corticosteroids 38 (70)
Near-fetal event in the past 10 (19)
a Inhaled corticosteroids, >1260 mg/day beclomethasone
dipropionate equivalent.
b Includes subject report of short-acting b2-agonist prophy-
lactic before exercise.
c Baseline pre-bronchodilator forced expiratory volume in one
second <80%.Next, the study subjects were divided into a slow decline
group (nZ 37) and a rapid decline group (nZ 17) based on
the FVC decline rate of 20 mL/year (Table 4). This value
was in agreement with the rate of annual FVC decline in
healthy adults estimated by the prediction formula of the
Japanese Respiratory Society. Compared to the slow
decline group, the subjects with rapid decline were
significantly older (p < 0.05), but smoking history and
evidence of atopy were not different between the groups.
The baseline FEV1/FVC ratio and FEV1% of predicted wereFigure 1 Distribution of estimated annual rates of change in
(A) forced vital capacity (FVC), and in (B) forced expiratory
volume in one second (FEV1) in patients with severe asthma.
Each bar represents changes in FVC or FEV1 of 10 mL/year.
Figure 2 Relationship between the annual rates of change in
forced expiratory volume in one second (DFEV1) and the annual
rates of change in forced vital capacity (DFVC) over a ten-year
period in patients with severe asthma. The r value was
Spearman’s correlation coefficient.
358 K. Matsunaga et al.similar between the groups, although the FVC % of pre-
dicted was significantly higher in the rapid decline group
(p < 0.01). The proportion of patients with baseline FVC of
more than 80% in the rapid decline group was 82%, but 49%
in the slow decline group (p < 0.05). The subjects with
rapid decline were more likely to show evidence of asthma
refractoriness including exacerbation rate (p < 0.05) and
use of OCS (p < 0.05). Furthermore, age (p < 0.05), base-
line FVC (p < 0.01), exacerbation rate (p < 0.05) and use of
OCS (p < 0.001) showed significantly negative correlations
with the rate of change in FVC (Fig. 3). The rapid decline
group had a tendency to receive more intensive asthma
treatment, but neither the dose of ICS nor other medication
use showed any difference between the groups (Table 4).Table 4 Characteristics of subjects subdivided by annual rates
Characteristics Slow decli
Age (years) 47.9  12.
Gender (female), n (%) 17 (45.9)
Body mass index (kg/mm2) 24.0  3.5
Smokers (current or ex), n (%) 15 (40.5)
Atopy, n (%) 33 (89.2)
Blood eosinophil count (%) 13.5  5.6
Serum total immunoglobulin E (IU/mL) 1203  15
FVC% of predicted (%) 79.1  14.
FEV1/FVC ratio (%) 69.5  10.
FEV1% of predicted (%) 54.5  11.
Annual exacerbation rate (events/year)c 0.37  0.4
Oral corticosteroids use (days/year)c 54.0  58.
Dose of inhaled corticosteroids (mg/day)c 1779  71
Inhaled long-acting b2-agonist use, n (%)d 26 (70.3)
Leukotriene receptor antagonist use, n (%)d 11 (26.7)
Theophylline use, n (%)d 24 (64.9)
Values are means  SD.
a 20 mL annual decline in FVC.
b >20 mL annual decline in FVC; characteristics are baseline values
c Mean values during follow-up period.
d Usage rate of medications during follow-up period.Discussion
In this observational study of patients with severe asthma,
we found that the faster obstructive changes detected by
FEV1 were accompanied by excessive loss of FVC, and the
reduction in FVC was more obvious than the FEV1 change.
The rate of change in both FVC and FEV1 over time was
highly variable. Moreover, age, baseline FVC, exacerbation
rate, and frequency of OCS use showed significantly nega-
tive correlations with the annual rate of change in FVC.
Several recent studies have suggested that there is
a difference in the pattern of airway obstruction between
severe and non-severe asthmatic patients.2,9 Moore et al.
compared subjects classified as having severe asthma with
subjects having moderate asthma. These groups were not
different with regard to FEV1, but the FVC was significantly
lower in the severe group.9 In addition, it has been shown
that severe asthma had prominent air trapping, evident as
reduced FVC over the entire range of FEV1/FVC, and this
obstructive pattern was confirmed with increased RV/TLC
(total lung capacity).2 Elevated RV/TLC has been shown as
a group characteristic of severe asthmatics,14 and air
trapping is related to airway closure or near closure.15,16
Since the FVC changes seemed to be caused by small
airway closure, peripheral airway dysfunction due to
vulnerable conditions may be responsible for the progres-
sion of the FVC reduction in severe asthma. Indeed,
Macklem’s group reported that severe asthmatic patients
who are treated with frequent systemic corticosteroids
often show decreased FVC by histamine inhalation chal-
lenge.17 In our study, the decline in FVC was more evident
than FEV1 in severe asthma, in agreement with previous
studies, suggesting that small airway susceptibility may be
the cause of rapid disease progression that becomes
refractory to asthma treatment.of decline in forced vital capacity.
nean Z 37 Rapid declinebn Z 17 pValue
6 55.4  12.4 <0.05
9 (52.9) 0.63
22.5  3.2 0.14
10 (58.8) 0.21
15 (88.2) 0.91
14.6  9.4 0.61
22 1631  2543 0.45
1 90.0  13.0 <0.01
0 64.3  10.3 0.09
8 58.9  14.4 0.24
3 0.71  0.60 <0.05
3 96.3  64.5 <0.05
9 1937  636 0.44
12 (70.6) 0.98
5 (29.4) 0.98
14 (82.4) 0.19
unless otherwise indicated.
Figure 3 Correlation between the annual rate of change in forced vital capacity (FVC) and age (A), baseline FVC (B), exacer-
bation rate (C), and frequency of oral corticosteroids use (D) in patients with severe asthma. The r value was Spearman’s
correlation coefficient.
Changes in airway obstruction in severe asthma 359Asthmatic patients are at risk of developing airway
obstruction. However, accelerated loss of lung function
over time has been shown in a subset of patients.8,10,11 It
has been widely accepted that severe asthma is charac-
terized by an accelerated decline in lung function.
However, surprisingly, few studies of patient cohorts have
provided detailed data, and there was considerable varia-
tion among the rates of FEV1 change.
18e21 Our data also
showed that lung function change in severe asthma was
highly variable, and only 31% of patients had a rate of FVC
decline of more than 20 mL/year. This phenomenon could
be partially explained by the fact that maintenance treat-
ment with ICS is associated with an attenuation of the lung
function decline in patients with asthma.19,22 These results
suggest that the rapid progression of airway obstruction
may not be a common feature of all severe asthma patients
receiving steroid therapy. In our study, the positive corre-
lation was found between DFVC and DFEV1 despite there
was a notable difference in the mean annual change rate in
two variables (DFVC, 9.1 mL/year; DFEV1, þ0.6 mL/
year). A recent study suggests that the changes in FVC and
FEV1 are affected differentially by underlying pathophysi-
ology despite having some predictable dependencies.2 Also,
this finding may partially due to the distribution of the
change in lung function among the subjects.
The role of asthma exacerbations in the accelerated loss
of lung function has not been fully elucidated. However,
a recent study suggested that intermittent period of
worsening airway inflammation during exacerbations, when
there is elevated expression of a variety of molecules that
may enhance airway remodeling, lead to greater declines in
lung function.20,22 Several in vivo studies have shown thatTh2 cytokines, including interleukin (IL)-4, IL-5, and IL-13,
stimulate epithelial cells and fibroblasts to promote a pro-
fibrotic response.23,24 In some asthmatics, the exhaled
nitric oxide fraction remains high despite ICS therapy,25 and
this persistent airway inflammation may be involved in the
aggravated decline in lung function.21 Systemic cortico-
steroids use is expected to suppress eosinophilic airway
inflammation, but conceivably could increase neutrophil
influx and thus airway damage.26,27 Although patients with
neutrophilic airway inflammation are more widely reported
in severe asthma,26 this may in part reflect the extent to
which patients have greater steroid exposure.27 Moreover,
the use of systemic steroids may contribute to a reduction
in the respiratory muscle force, particularly in elderly
patients with asthma.28 It has been also suggested that
reductions of lung elastic recoil may be abnormal in
asthma, and that lung elasticity decreases particularly with
age.29,30 Indeed, in our study, elderly patients with severe
asthma were at increased risk for excess FVC decline.
Interestingly, a previous study showed that asthma exac-
erbations are associated with acute loss in lung elasticity.31
Further study is needed to assess whether repeated exac-
erbations of asthma result in permanent reductions of lung
elastic recoil. In our study, a higher baseline FVC was
associated with a rapid decline in FVC. This may be related
to the fact that subjects with slow decline had lower FVC,
thus providing less capacity for FVC to decline over time.
Our study had several limitations. First, since this was
a purely observational study, the drugs administered in
addition to ICS were not able to be standardized throughout
the study period. Second, a selection bias is possible
because the determination of asthma severity was made on
360 K. Matsunaga et al.the basis of past medical records. Finally, the majority of
the patients who were eligible had been living in an urban
area of Japan, and so the possibility that air pollution
affected the long-term history of asthma could not be
excluded.32
In conclusion, we have shown that the decline in FVC is
more evident than FEV1 in severe/refractory asthma, sug-
gesting that small airway susceptibility may be the cause of
rapid disease progression, and effective intervention in
that area could improve the management efficacy. More-
over, aging, exacerbations of asthma, and use of systemic
corticosteroids are associated with greater FVC decline,
particularly if FVC is still normal.Conflict of interest statement
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